McLean1991 - Behaviour of HIV in the presence of zidovudine
Ontology highlight
ABSTRACT:
SUBMITTER: 
Sathvik Anantakrishnan
PROVIDER: BIOMD0000000967 | BioModels | 2020-10-15
REPOSITORIES: BioModels
Publications
Population dynamics of HIV within an individual after treatment with zidovudine.
McLean A R AR Emery V C VC Webster A A Griffiths P D PD
AIDS (London, England) 19910501 5
A new mechanism is proposed for the apparent breakthrough of HIV that occurs approximately 6 months after the commencement of therapy with zidovudine (AZT). Using a simple mathematical model of the interacting population dynamics of HIV and its major host cell in the circulation (the CD4+ lymphocyte), predicted patterns of HIV plasma viraemia in the weeks following treatment with zidovudine are generated. These are in close agreement with observed patterns despite the fact that the model contain ...[more]
Similar Datasets
Project description:Objective: to compare changes in gene expression by microarray from subcutaneous adipose tissue from HIV treatment naïve patients treated with efavirenz based regimens containing abacavir (ABC), tenofavir (TDF) or zidovidine (AZT). There were significant divergence between ABC and the other two groups 6 months after treatment in genes controlling cell adhesion and environmental information processin, with some convergence at 18 months. Compared to HIV negative controls the ABC group, but not AZT or TDF, showed enrichment of genes controlling adherence junction at six months and 184 months (adjusted p <0.05), and cell matrix adhesion (adjusted p<3.4E-0.5) at 6 months. Tight junction (p=0.03), gap junction (p<0.05) and leukocyte transendothelial migration (p=0.03) were over-expressed in ABC compared to TDF at 6 m. Enrichment pathways and individual genes controlling cell adhesion and environmental information processing were specifically dysregulated in the ABC group compared with the other treatments, There was little difference between AZT and TDF. Conclusion: After initiating treatment, there is divergence in the expression of genes controlling cell adhesion and environmental information processing between ABC and both TDF and AZT in subcutaneous adipose tissue. If similar changes are taking place in other tissues including the coronary vasculature, they may contribute to the observed increased risk of cardiovascular events reported in patients recently started on abacavir-containing regimens.
2015-04-16 | GSE62117 | GEO
Project description:Objective: to compare changes in gene expression by microarray from subcutaneous adipose tissue from HIV treatment naïve patients treated with efavirenz based regimens containing abacavir (ABC), tenofavir (TDF) or zidovidine (AZT). There were significant divergence between ABC and the other two groups 6 months after treatment in genes controlling cell adhesion and environmental information processin, with some convergence at 18 months. Compared to HIV negative controls the ABC group, but not AZT or TDF, showed enrichment of genes controlling adherence junction at six months and 184 months (adjusted p <0.05), and cell matrix adhesion (adjusted p<3.4E-0.5) at 6 months. Tight junction (p=0.03), gap junction (p<0.05) and leukocyte transendothelial migration (p=0.03) were over-expressed in ABC compared to TDF at 6 m. Enrichment pathways and individual genes controlling cell adhesion and environmental information processing were specifically dysregulated in the ABC group compared with the other treatments, There was little difference between AZT and TDF. Conclusion: After initiating treatment, there is divergence in the expression of genes controlling cell adhesion and environmental information processing between ABC and both TDF and AZT in subcutaneous adipose tissue. If similar changes are taking place in other tissues including the coronary vasculature, they may contribute to the observed increased risk of cardiovascular events reported in patients recently started on abacavir-containing regimens. 31 HIV treatment naïve patients were randomised to receive either zidovidine (AZT)/lamivudine or tenofavir (TDF)/emtricitabine in fixed dose preparations. Both groups also received efavirenz. Patients were tested before treatment (AZT n=15, TDF n=16) and at 6 (AZT n=9, TDF n=12) and 18-24 (AZT n= 8, TDF n=9) months after starting therapy. Tests included extensive biochemical tests, tests of body fat distribution and subcutaneous fat biopsies. 15 HIV negative patients were similarly tested. Patients and controls were matched for age, ethnicity, gender, weight, BMI, pretreatment CD4 count, viral load, and family history of cardiovascular disease and diabetes. In a second part of the study patients on their initial antiretroviral regimen containihg abacavir (ABC)/lamivudine plus efavirenz for 6 months (n=9) and 184 months (n=10) were similarly tested. the ABC-treated group were matched in all the listed characteristice with the other two groups. None of the patients had ever experienced an AIDS-defining disease or developed lipodystrophy over the study period. Fat biopsies were snap frozen until assayed. Microarray methods: RNA was extracted for microarray and array data generated using a Qiagen RNeasy Lipid Tissue Mini Kit. Total RNA was converted into labeled cDNA using the WT-Ovation Pico RNA Amplification System and samples were hybridized to an Agilent Whole Human Genome Microarray 4x44K (AMADID 014850, Agilent Technologies). The Agilent arrays were scanned with the Agilent Technologies DNA Microarray Scanner G2505C with default settings. Scanned images were extracted and initial quality control performed in Agilent Feature Extraction (AFE) software version 10.7.3.1. Additional quality assessment was performed using the R arrayQualityMetrics package. As no major experimental problems could be detected, all microarrays were included in subsequent analysis steps. The dataset was read into R and processed using the Agi4x44PreProcess package with options to use the AFE Processed Signal as foreground signal and BG Used signal as background adjusted signal. The data were then normalized by the quantile method using the limma function normalize Between Arrays. Probeset filtering was performed using the Agi4x44PreProcess filter method using AFE provided flags to identify features with quantification errors of the signal, reducing the 45,015 features on the Agilent Whole Human Genome Microarray 4x44K array by 38%, or 17,264 features. Residual technical batch effects were corrected using the ComBat method implemented in the SVA R package.Since patients were not randomised to the ABC treatment all samples were treated as unrelated. Gene expression differences between treatment arms were assessed using the linear modeling features implemented in the limma package in R. Multiple testing across contrasts was performed using the limma global method with Benjamini-Hochberg approach for control of false discovery rate (FDR). Gene set enrichment analysis of GO terms and KEGG pathways was performed using the conditional hypergeometric test implemented in the GOstats R package. Statistical significance of gene set enrichment was performed using the Benjamini-Hochberg correction method implemented in the EMA R package .
2015-04-16 | E-GEOD-62117 | biostudies-arrayexpress
Project description:Initiation of antiretroviral therapy during the earliest stages of HIV-1 infection may limit the seeding of a long-lasting viral reservoir, but long-term effects of early antiretroviral treatment initiation remain unknown. Here, we analyzed immunological and virological characteristics of nine patients who started antiretroviral therapy in primary HIV-1 infection and remained on suppressive treatment for >10 years; patients with similar treatment duration but initiation of therapy in chronic HIV-1 infection served as controls. We observed that independently of the timing of treatment initiation, HIV-1 DNA in CD4 T cells decayed exclusively during the initial 3-4 years of treatment; however, in patients who started antiretroviral therapy in acute infection, this decay occurred faster and was more pronounced, leading to substantially lower levels of cell-associated HIV-1 DNA after long-term treatment. Despite this smaller size, the viral CD4 T cell reservoir in persons with early treatment initiation consisted more dominantly of the long-lasting central-memory and T memory stem cells. Moreover, gene transcripts in CD4 T cells associated with the total viral CD4 T cell reservoir size frequently correlated with the relative proportion of these long-lived CD4 T cell subsets, suggesting shared gene expression signatures for maintaining HIV-1 persistence and preservation of long-lasting CD4 T cell subsets. Despite effective suppression of viral antigens for >10 years, HIV-1-specific T cell responses remained continuously detectable in both study groups. Together, these data suggest that although early HIV-1 treatment initiation, even when continued for >10 years, is unlikely to lead to viral eradication, the presence of low viral reservoirs and durable HIV-1 T cell responses may make such patients attractive candidates for future interventional studies aiming at HIV-1 eradication and cure.
2017-01-01 | GSE53527 | GEO
Project description:The epigenetic mechanisms established by histone modifications may affect the transcriptional silencing of HIV-1 and viral latency. A systematic epigenome profiling could be applicable to develop new epigenetic diagnostic markers for detecting HIV-1 latency. In this study, histone modification profiles of HIV-1 latency cell lines were compared with those of uninfected CD4+ T cell line. The HIV-1 latency gave rise to differential histone modification regions. The differential enrichment patterns helped us to define potential effector genes leading to the viral latency. The histone H3K4me3 and H3K9ac profiles were obtained from the HIV-1 latency cell lines (NCHA1, NCHA2, and ACH2) and control CD4+ T cell line (A3.01)
2014-06-06 | E-GEOD-58247 | biostudies-arrayexpress
Project description:Human Immunodeficiency Virus type-1 (HIV-1)-infected individuals show metabolic alterations of CD4 T cells through unclear mechanisms with undefined consequences. We analyzed the transcriptome of CD4 T cells from HIV-1 patients and revealed that elevated oxidative phosphorylation (OXPHOS) pathway is associated with poor outcomes. Inhibition of OXPHOS by the FDA-approved drug metformin, which targets mitochondrial respiratory chain complex I, suppresses HIV-1 replication in human CD4 T cells and humanized mice. In patients, HIV-1 peak viremia positively correlates with the expression of NLRX1, a mitochondrial innate immune receptor. Quantitative proteomics and metabolic analyses reveal that NLRX1 enhances OXPHOS and glycolysis during HIV-1-infection of CD4 T cells to promote viral replication. At the mechanistic level, HIV infection induces the association of NLRX1 with the mitochondrial protein, FASTKD5, to promote the expression of mitochondrial respiratory complex components. This study uncovers the OXPHOS pathway in CD4 T cells as a target for HIV-1 therapy.
2022-02-16 | PXD023565 | Pride
Project description:Retroviral integration is mediated by a unique enzymatic process shared by all retroviruses and retrotransposons. During integration, double-stranded linear viral DNA is inserted into the host genome in a process catalyzed by viral-encoded integrase. However, host cell defenses against HIV-1 integration are not clear. This study identifies -catenin-like protein 1 (CTNNBL1) as a potent inhibitor of HIV-1 integration via association with viral IN and its cofactor, lens epithelium-derived growth factor/p75. CTNNBL1 overexpression blocks HIV-1 integration and inhibits viral replication, whereas CTNNBL1 depletion significantly upregulates HIV-1 integration into the genome of various target cells. Further, CTNNBL1 expression is downregulated in CD4+ T cells by activation, and CTNNBL1 depletion also facilitates HIV-1 integration in resting CD4+ T cells. Thus, host cells may employ CTNNBL1 to inhibit HIV-1 integration into the genome. This finding suggests a strategy for the treatment of HIV infections.
2022-02-24 | PXD031853 | iProX
Project description:We invesitgated cellular pathways required for HIV-1 activation using HIV-1-suppressing agents. Despite effective antiretroviral therapy, HIV-1-nfected cells continue to produce viral antigens and induce chronic immune exhaustion. Using a novel dual reporter system and a high-throughput drug screen, we identified FDA-approved drugs which can suppress HIV-1 reactivation in both cell line models and CD4+ T cells from virally suppressed, HIV-1-infected individuals. We identified 11 cellular pathways required for HIV-1 reactivation as druggable targets. Using differential expression analysis, gene set enrichment analysis and exon-intron landscape analysis, we examined the impact of drug treatment on the cellular environment at a genome-wide level.
2020-09-02 | GSE149353 | GEO
Project description:Wodarz2007 - HIV/CD4 T-cell interaction
A deterministic model illustrating how
CD4 T-cells can influence HIV infection.
This model is described in the article:
Infection dynamics in
HIV-specific CD4 T cells: does a CD4 T cell boost benefit the
host or the virus?
Wodarz D, Hamer DH.
Math Biosci 2007 Sep; 209(1):
14-29
Abstract:
Recent experimental data have shown that HIV-specific CD4 T
cells provide a very important target for HIV replication. We
use mathematical models to explore the effect of specific CD4 T
cell infection on the dynamics of virus spread and immune
responses. Infected CD4 T cells can provide antigen for their
own stimulation. We show that such autocatalytic cell division
can significantly enhance virus spread, and can also provide an
additional reservoir for virus persistence during anti-viral
drug therapy. In addition, the initial number of HIV-specific
CD4 T cells is an important determinant of acute infection
dynamics. A high initial number of HIV-specific CD4 T cells can
lead to a sudden and fast drop of the population of
HIV-specific CD4 T cells which results quickly in their
extinction. On the other hand, a low initial number of
HIV-specific CD4 T cells can lead to a prolonged persistence of
HIV-specific CD4 T cell help at higher levels. The model
suggests that boosting the population of HIV-specific CD4 T
cells can increase the amount of virus-induced immune
impairment, lead to less efficient anti-viral effector
responses, and thus speed up disease progression, especially if
effector responses such as CTL have not been sufficiently
boosted at the same time.
This model is hosted on
BioModels Database
and identified by:
BIOMD0000000663.
To cite BioModels Database, please use:
Chelliah V et al. BioModels: ten-year
anniversary. Nucl. Acids Res. 2015, 43(Database
issue):D542-8.
To the extent possible under law, all copyright and related or
neighbouring rights to this encoded model have been dedicated to
the public domain worldwide. Please refer to
CC0
Public Domain Dedication for more information.
2018-01-22 | BIOMD0000000663 | BioModels
Project description:HIV latency is a major obstacle to curing infection. Current strategies to eradicate HIV aim at increasing transcription of the latent provirus. In the present study we observed that latently infected CD4+ T cells from HIV-infected individuals failed to produce viral particles upon ex vivo exposure to SAHA (vorinostat), despite effective inhibition of histone deacetylases. To identify steps that were not susceptible to the action of SAHA or other latency reverting agents, we used a primary CD4+ T cell model, joint host and viral RNA sequencing, and a viral-encoded reporter. This model served to investigate the characteristics of latently infected cells, the dynamics of HIV latency, and the process of reactivation induced by various stimuli. During latency, we observed persistence of viral transcripts but only limited viral translation. Similarly, the reactivating agents SAHA and disulfiram successfully increased viral transcription, but failed to effectively enhance viral translation, mirroring the ex vivo data. This study highlights the importance of post-transcriptional blocks as one mechanism leading to HIV latency that needs to be relieved in order to purge the viral reservoir.
2017-02-24 | GSE95297 | GEO
Project description:We evaluated longitudinal changes in viral replication and emergence of viral variants in the context of T cell homeostasis and gene expression in GALT of three HIV-positive patients who initiated HAART during primary HIV infection but opted to interrupt therapy thereafter. Longitudinal viral sequence analysis revealed that a stable proviral reservoir was established in GALT during primary HIV infection that persisted through early HAART and post-therapy interruption. Proviral variants in GALT and peripheral blood mononuclear cells (PBMCs) displayed low levels of genomic diversity at all times. A rapid increase in viral loads with a modest decline of CD4 T cells in peripheral blood was observed, while gut mucosal CD4 T cell loss was severe following HAART interruption. This was accompanied by increased mucosal gene expression regulating interferon (IFN)-mediated antiviral responses and immune activation, a profile similar to those found in HAART-naive HIV-infected patients. Gut mucosal responses to HAART interruption were evaluated with Affymetrix arrays
2011-03-25 | E-GEOD-28177 | biostudies-arrayexpress